New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
08:12 EDTKERXKeryx Biopharmaceuticals announces filing of NDA for Ferric Citrate in Japan
Keryx Biopharmaceuticals announced that its Japanese partner, Japan Tobacco, has filed its New Drug Application with the Japanese Ministry of Health, Labour and Welfare for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease. The NDA filing is supported by efficacy and safety data from several successfully completed Phase 3 studies in CKD patients with hyperphosphatemia in Japan. Under the license agreement with JT and its subsidiary Torii Pharmaceutical Co. within 30 days, Keryx will receive a non-refundable payment of $7M for the achievement of the NDA filing milestone.
News For KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 21, 2015
19:55 EDTKERXKeryx 9.17M share Secondary priced at $12.00
The deal size was raised to 9.17M shares from 7.2M shares. JPMorgan acted as sole book running manager for the offering.
January 20, 2015
18:30 EDTKERXOn The Fly: After Hours Movers
Subscribe for More Information
16:06 EDTKERXKeryx files to sell $100M in common stock
J.P. Morgan is acting as the sole book-running manager in the offering. Keryx intends to use the net proceeds from the sale of its common stock to fund the ongoing commercialization and development of Auryxia in the US, pre-commercial activities in Europe, to potentially in-license, acquire and develop additional drug candidates, and other general corporate purposes.
January 12, 2015
05:12 EDTKERXKeryx names COO Greg Madison as CEO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use